{"transactions":[{"id":2649755,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"ATP Life Science Ventures, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T20:32:08.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":17161713,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares were directly held by ATP. ATP III GP, Ltd. (\"ATP GP\") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-21-006113","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000106299321006113/form4.xml","form_type":"4"}},{"id":2650214,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"ATP Life Science Ventures, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T16:31:38.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":5830203,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. (\"ATP,\" and formerly known as Apple Tree Partners IV, L.P.)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares were directly held by ATP. ATP III GP, Ltd. (\"ATP GP\") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-21-006112","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000106299321006112/form4.xml","form_type":"4"}},{"id":2966178,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-25T22:01:02.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":375000,"price":39,"value":14625000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Represents shares held by Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\") is the sole general partner of ATP IV. Seth Harrison, a director of the issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV, but disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":17161713,"source":{"system":"sec-edgar","filing":"0001209191-20-060542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919120060542/doc4.xml","form_type":"4"}},{"id":3083711,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-14T16:46:23.000Z","date":"2020-07-10","kind":"purchase","acquired":true,"shares":415000,"price":36,"value":14940000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 10, 2020, Apple Tree Partners, IV, L.P. (\"ATP\") purchased 415,000 shares of common stock of the Issuer at a price of $36.00 per share pursuant to an underwritten public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by ATP. ATP III GP, Ltd. (\"ATP GP\") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein."}],"balance_after":5830203,"source":{"system":"sec-edgar","filing":"0001104659-20-083455","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465920083455/a4.xml","form_type":"4"}},{"id":3478799,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-06-25T18:04:37.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":880568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These shares are owned directly by ATP. ATP III GP, Ltd.(\"ATP GP\") is the sole general partner of ATP.   Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP.  ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":286439},"source":{"system":"sec-edgar","filing":"0001104659-19-037457","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037457/a4.xml","form_type":"4"}},{"id":3478798,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-06-25T18:04:37.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":13000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These shares are owned directly by ATP. ATP III GP, Ltd.(\"ATP GP\") is the sole general partner of ATP.   Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP.  ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4228764},"source":{"system":"sec-edgar","filing":"0001104659-19-037457","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037457/a4.xml","form_type":"4"}},{"id":3478797,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T18:04:37.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":900000,"price":16,"value":14400000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These shares are owned directly by ATP. ATP III GP, Ltd.(\"ATP GP\") is the sole general partner of ATP.   Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP.  ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein."}],"balance_after":5415203,"source":{"system":"sec-edgar","filing":"0001104659-19-037457","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037457/a4.xml","form_type":"4"}},{"id":3478796,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T18:04:37.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":286439,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These shares are owned directly by ATP. ATP III GP, Ltd.(\"ATP GP\") is the sole general partner of ATP.   Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP.  ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein."}],"balance_after":4515203,"source":{"system":"sec-edgar","filing":"0001104659-19-037457","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037457/a4.xml","form_type":"4"}},{"id":3478795,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T18:04:37.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":4228764,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. (\"ATP\") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All series of  preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These shares are owned directly by ATP. ATP III GP, Ltd.(\"ATP GP\") is the sole general partner of ATP.   Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP.  ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein."}],"balance_after":4228764,"source":{"system":"sec-edgar","filing":"0001104659-19-037457","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919037457/a4.xml","form_type":"4"}},{"id":3481425,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-06-21T20:59:31.000Z","date":"2019-06-21","kind":"exercise","acquired":false,"shares":2799910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2799910},"source":{"system":"sec-edgar","filing":"0001567619-19-013838","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/doc1.xml","form_type":"4"}},{"id":3481424,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2019-06-21T20:59:31.000Z","date":"2019-06-21","kind":"exercise","acquired":false,"shares":7617746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7617746},"source":{"system":"sec-edgar","filing":"0001567619-19-013838","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/doc1.xml","form_type":"4"}},{"id":3481423,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-06-21T20:59:31.000Z","date":"2019-06-21","kind":"exercise","acquired":false,"shares":4980168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4980168},"source":{"system":"sec-edgar","filing":"0001567619-19-013838","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/doc1.xml","form_type":"4"}},{"id":3481422,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T20:59:31.000Z","date":"2019-06-21","kind":"purchase","acquired":true,"shares":1388889,"price":18,"value":25000002.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":16786713,"source":{"system":"sec-edgar","filing":"0001567619-19-013838","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/doc1.xml","form_type":"4"}},{"id":3481421,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T20:59:31.000Z","date":"2019-06-21","kind":"exercise","acquired":true,"shares":2799910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":15397824,"source":{"system":"sec-edgar","filing":"0001567619-19-013838","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/doc1.xml","form_type":"4"}},{"id":3481420,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T20:59:31.000Z","date":"2019-06-21","kind":"exercise","acquired":true,"shares":7617746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":12597914,"source":{"system":"sec-edgar","filing":"0001567619-19-013838","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/doc1.xml","form_type":"4"}},{"id":3481419,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":105820,"kind":"organization","name":"ATP Life Science Ventures, L.P.","position":1,"cik":"0001593440","reported_name":"Apple Tree Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105819,"kind":"organization","name":"ATP III GP, Ltd.","position":2,"cik":"0001593453","reported_name":"ATP III GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T20:59:31.000Z","date":"2019-06-21","kind":"exercise","acquired":true,"shares":4980168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Apple Tree Partners IV, L.P. (\"ATP IV\"). ATP III GP, Ltd. (\"ATP III\"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":4980168,"source":{"system":"sec-edgar","filing":"0001567619-19-013838","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/doc1.xml","form_type":"4"}}]}